Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

441
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
441
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

398
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
398
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

3.8K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.8K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

403
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
403
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

390
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
390
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

347
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
347

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of HbA1c and Time in Range in the Prediction of Large for Gestational Age in Pregnancies Involving Type 1 Diabetes.

Diagnostics (Basel, Switzerland)·2026
Same author

Vitamin D deficiency in pregnant women: obstetric implications and clinical management.

Ginekologia polska·2026
Same author

Impact of light on the human body with particular emphasis on women's reproductive health.

Ginekologia polska·2026
Same author

The impact of melatonin on intrauterine growth restriction.

Ginekologia polska·2026
Same author

The Effect of Oral Supplementation with a Multi-Strain Probiotic Preparation on Group B Streptococcus (GBS) Carriage in Pregnant Women-A Pilot Study.

Journal of clinical medicine·2026
Same author

Search for the most precise diagnosis of monogenic diabetes - the usefulness of short-read NGS method in molecular testing in Polish patients.

Acta diabetologica·2026

Related Experiment Video

Updated: Nov 17, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.1K

Metformin administration during pregnancy - current insight.

Milena Skibinska1,2, Monika Zurawska-Klis3, Michal Krekora4

  • 1Department of Obstetrics and Gynecology, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland. milena.skibinska@stud.umed.lodz.pl.

Ginekologia Polska
|February 12, 2021
PubMed
Summary

Metformin may be a promising treatment for gestational diabetes mellitus (GDM) due to its insulin-sensitizing effects. While not first-line, its use in pregnancy is considered when other options fail, with some evidence suggesting safety for mother and fetus.

Keywords:
GDMdiabetes mellitusmetforminpregnancy

More Related Videos

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.9K
Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs
08:15

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

705

Related Experiment Videos

Last Updated: Nov 17, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.1K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.9K
Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs
08:15

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

705

Area of Science:

  • Obstetrics and Gynecology
  • Endocrinology
  • Pharmacology

Background:

  • Gestational diabetes mellitus (GDM) is primarily driven by insulin resistance.
  • Metformin, a drug that reduces insulin resistance, presents a potential therapeutic option for GDM.
  • Current guidelines often do not recommend metformin as a first-line GDM treatment during pregnancy.

Purpose of the Study:

  • To review the current evidence on the use of metformin during pregnancy for GDM.
  • To discuss the safety profile of metformin in pregnant individuals and its potential effects on fetal development.
  • To analyze existing recommendations regarding metformin use in GDM management.

Main Methods:

  • Literature review of current studies and clinical recommendations.
  • Analysis of evidence regarding obstetric complications and fetal outcomes.
  • Discussion of metformin's placental transfer and potential long-term effects.

Main Results:

  • Some evidence suggests metformin use in pregnancy is not associated with increased obstetric complications.
  • Metformin crosses the placenta, raising concerns about potential long-term effects on child development.
  • Metformin is permissible in GDM management when insulin treatment is not feasible.

Conclusions:

  • Metformin's role in GDM management requires careful consideration due to placental transfer.
  • Further research is needed to fully understand the long-term safety of metformin for children exposed in utero.
  • Current recommendations allow metformin use in specific GDM scenarios, balancing risks and benefits.